Holen Sie sich die Stockscreener-App
78.48
0.71%
0.55
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CVS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$77.93
Offen:
$77.75
24-Stunden-Volumen:
6.72M
Relative Volume:
0.81
Marktkapitalisierung:
$99.84B
Einnahmen:
$402.11B
Nettoeinkommen (Verlust:
$1.73B
KGV:
56.73
EPS:
1.3835
Netto-Cashflow:
$7.81B
1W Leistung:
+0.17%
1M Leistung:
-2.73%
6M Leistung:
+19.09%
1J Leistung:
+18.25%
1-Tages-Spanne:
$77.65
$79.09
1-Wochen-Bereich:
$73.00
$79.09
52-Wochen-Spanne:
$58.35
$85.15
Cvs Health Corp Stock (CVS) Company Profile
Firmenname
Cvs Health Corp
Sektor
Branche
Telefon
(401) 765-1500
Adresse
ONE CVS DR., WOONSOCKET
Compare CVS vs UNH, CI, ELV, HUM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
78.48 | 99.14B | 402.11B | 1.73B | 7.81B | 1.3835 |
|
UNH
Unitedhealth Group Inc
|
293.19 | 257.59B | 447.57B | 12.81B | 16.08B | 13.19 |
|
CI
Cigna Group
|
291.44 | 75.77B | 216.66B | 6.25B | 7.44B | 22.19 |
|
ELV
Elevance Health Inc
|
346.80 | 74.17B | 199.13B | 5.66B | 3.17B | 25.11 |
|
HUM
Humana Inc
|
184.10 | 21.51B | 126.36B | 1.30B | 1.55B | 10.67 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | Goldman | Buy |
| 2025-08-18 | Hochstufung | UBS | Neutral → Buy |
| 2025-08-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Edward Jones | Hold → Buy |
| 2024-12-03 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-05-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-05-02 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-22 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Herabstufung | Edward Jones | Buy → Hold |
| 2023-05-26 | Eingeleitet | Piper Sandler | Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Eingeleitet | Goldman | Buy |
| 2021-12-01 | Eingeleitet | Seaport Research Partners | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-01-08 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-17 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-05-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-06-05 | Hochstufung | Standpoint Research | Hold → Buy |
| 2019-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Eingeleitet | Guggenheim | Buy |
| 2019-04-15 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-13 | Eingeleitet | Bernstein | Outperform |
| 2019-02-20 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-18 | Eingeleitet | Barclays | Overweight |
| 2018-11-29 | Fortgesetzt | Goldman | Neutral |
| 2018-11-28 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-26 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2018-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-02-27 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-02-13 | Bestätigt | Citigroup | Neutral |
Alle ansehen
Cvs Health Corp Aktie (CVS) Neueste Nachrichten
Saggio Realty Announces Milestone Linked to Sale of Marco Island’s CVS-Anchored Plaza - GlobeNewswire Inc.
CVS Pharmacy Is Quietly Becoming Your All?in?One Health Hub — Here’s What Shoppers Are Really Sa - AD HOC NEWS
Humana is said to be near $1B deal for MaxHealth - Modern Healthcare News
Big Health Raises $23.7M from .406 Ventures, AlleyCorp, CVS Ventures, Blue Venture Fund - Behavioral Health Business
CVS Health Reports Strong Earnings, Optimistic 2026 Outlook - Intellectia AI
Analysts See Multiple Growth Levers For CVS In 2026 - Benzinga
Is CVS’s Reaffirmed 2026 EPS Guidance Amid Medicare Advantage Uncertainty Altering The Investment Case For CVS Health (CVS)? - Yahoo Finance
Humana’s profit outlook adds to health insurance gloom - Modern Healthcare News
CVS Q4 Deep Dive: Pharmacy Turnaround and Regulatory Shifts Shape Outlook - Finviz
Mark Cuban Urges Trump To 'Put His Weight Behind' Josh Hawley, Elizabeth Warren's 'Break Up Big Medicine Act' - Benzinga
Decoding CVS Health Corp (CVS): A Strategic SWOT Insight - GuruFocus
CVS Health Q4 Earnings Call Highlights - Yahoo Finance
CVS defends its scale as CEO Joyner aligns with Trump, blames pharma for high costs - The Business Journals
CVS Health Earnings Call: Cash, Growth And Cost Risks - TipRanks
CVS annual profit guidance misses Wall Street estimates - The Boston Globe
CVS Health Corp (CVS) Q4 2025 Earnings Call Highlights: Strong R - GuruFocus
CVS Reiterates 2026 Profit Outlook, Shares Slide 3.7% Despite Q4 Beat - TradingView
CVS year-end profit falls to $1.7B in 2025 - Providence Business News
What's Going On With CVS Health Stock Tuesday?CVS Health (NYSE:CVS) - Benzinga
House subpoenas CVS, Kaiser Permanente, others in ACA fraud probe - Modern Healthcare News
Gold Moves Lower; CVS Health Earnings Top Views - Benzinga
CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline - AlphaStreet News
CVS Health (CVS) Surpasses Expectations with Strong 2025 Performance - GuruFocus
CVS Health grapples with high costs, strategic reset - Modern Healthcare News
CVS Health Reports Strong Q4 2025 Earnings with Positive Outlook - Intellectia AI
CVS Earnings: 2026 Guidance Maintained After Strong Trends In Late 2025 - Morningstar
CVS Anticipates Medicare Margin Growth by 2026 - GuruFocus
CVS Faces Challenges with Proposed Rates Amid Rising Costs - GuruFocus
Jim Cramer on CVS: "I Think It's a Fascinating Time to Own the Stock" - Finviz
Jim Cramer on CVS: “I Think It’s a Fascinating Time to Own the Stock” - Insider Monkey
CVS Health Q4 2025 slides: Revenue jumps 8.2%, stock falls despite earnings beat - Investing.com
CVS Health posts strong Q4 revenue, raises full-year guidance - Proactive financial news
Earnings call transcript: CVS Health Q4 2025 beats forecasts, stock dips By Investing.com - Investing.com India
CVS Keeps 2026 Forecast Steady Amid Tumult in Health Insurance - Bloomberg.com
Earnings call transcript: CVS Health Q4 2025 beats forecasts, stock dips - Investing.com
CVS Health (CVS) Subpoenaed in ACA Fraud Investigation - GuruFocus
AI for investors - MLQ.ai
CVS Beats Q4 Revenue Estimates, Highlights Strategic Growth - GuruFocus
CVS Forecasts FY26 Operating Income in Billions - GuruFocus
CVS Maintains FY26 Effective Tax Rate Projection at 25.3% - GuruFocus
Republican-led House panel issues subpoenas to eight health insurers: Axios - CNBC
CVS Health Reports Q4 Beat but Maintains Full-Year Outlook - Intellectia AI
CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
CVS Health (NYSE:CVS) Surprises With Q4 CY2025 Sales - Finviz
CVS Health Corp (NYSE:CVS) Beats Q4 Estimates but Shares Dip on Cautious Outlook - ChartMill
CVS Lowers Fiscal Year 2026 Cash Flow Outlook - GuruFocus
CVS Health (CVS) Surpasses Q4 Expectations with Strong Revenue G - GuruFocus
CVS Health beats Q4 expectations, cash flow guidance lowered - Investing.com
CVS Health Insiders Placed Bullish Bets Worth US$2.10m - Yahoo Finance
CVS Health beats quarterly profit expectations on pharmacy performance By Reuters - Investing.com
CVS HEALTH Corp SEC 10-K Report - TradingView
Finanzdaten der Cvs Health Corp-Aktie (CVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):